DBV Preclinical Data Says Their Immunotherapy Is Long-Term

Author:
Publish date:
Research.jpg

According to newly-published study results, preclinical data for the EPIT food allergy treatment system is longer term than expected. The results show that animals who've completed the therapy and are no longer on it continue to have protection against anaphylaxis four weeks later.

DBV Technologies is working towards efficacy and approval for their Epicutaneous Immunotherapy (EPIT) food allergy patch. The new preclinical results have been published in the Journal of Allergy and Clinical Immunology.

Food allergic mice treated with the EPIT system ("Viaskin") showed long-term results.

Before, during and after the Viaskin treatments, the mice were subjected to food allergen proteins via tissue sampling. Measurements indicated that before and early into the EPIT treatment, the mice were likely to go into anaphylactic shock. Towards the end of treatment and for four weeks afterwards, they were not.

DBV says that this is very encouraging news and that they are preparing for clinical trials upon government approval.

This website and story author are not affiliated with DBV Technologies.

Source: GlobeNewsWire.com

Related